Professor Emeritus Mark Turner is a retired Neonatologist with a passion for improving the medicines that are given to babies and children.
As a Co-Investigator or Principal Investigator in multicentred studies of 14 medicines and 3 excipients, he has examined methods to evaluate drug safety, medicines administration and the costs of off-label medicines.
Prof Turner drove the setup of the 20 country pan-European paediatric Clinical Trials Network funded by IMI2, conect4chidren (c4c) and was co-Coordinator of that project with responsibility for the setup and implementation of the network (including the allocation of €25 million funding for clinical trials). Prof Turner is now the CEO of the c4c non-profit foundation (Stichting) as the transition was made from a grant-funded phase of development to a sustainable organization.
He contributed to the development of five European research infrastructures and one in the USA. He chaired the European Network of Paediatric Research at the European Medicines Network for six years. He is the European Co-Director of the International Neonatal Consortium, hosted by the Critical Path Institute and funded by the FDA and industry. He was President of the European Society for Developmental, Perinatal and Paediatric Pharmacology 2019 – 2022.
